GT Biopharma, Inc. GTBP
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 41.97% | -42.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 58.43% | -49.10% | |||
| Operating Income | -58.43% | 49.10% | |||
| Income Before Tax | -59.48% | 87.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -59.48% | 87.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -59.48% | 87.70% | |||
| EBIT | -58.43% | 49.10% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -6.32% | 95.00% | |||
| Normalized Basic EPS | -24.41% | 94.73% | |||
| EPS Diluted | -6.32% | 95.00% | |||
| Normalized Diluted EPS | -24.41% | 94.73% | |||
| Average Basic Shares Outstanding | 28.19% | 133.35% | |||
| Average Diluted Shares Outstanding | 28.19% | 133.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||